Literature DB >> 11563055

Telomerase inhibitors--oligonucleotide phosphoramidates as potential therapeutic agents.

S Gryaznov1, K Pongracz, T Matray, R Schultz, R Pruzan, J Aimi, A Chin, C Harley, B Shea-Herbert, J Shay, Y Oshima, A Asai, Y Yamashita.   

Abstract

We have designed, synthesized, and evaluated using physical, chemical and biochemical assays various oligonucleotide N3'-->P5' phosphoramidates, as potential telomerase inhibitors. Among the prepared compounds were 2'-deoxy, 2'-hydroxy, 2'-methoxy, 2'-ribo-fluoro, and 2'-arabino-fluoro oligonucleotide phosphoramidates, as well as novel N3'-->P5' thio-phosphoramidates. The compounds demonstrated sequence specific and dose dependent activity with IC50 values in the sub-nM to pM concentration range.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563055     DOI: 10.1081/NCN-100002314

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  14 in total

Review 1.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

Review 2.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

3.  DNA polymerase activity on synthetic N3'→P5' phosphoramidate DNA templates.

Authors:  Victor S Lelyveld; Derek K O'Flaherty; Lijun Zhou; Enver Cagri Izgu; Jack W Szostak
Journal:  Nucleic Acids Res       Date:  2019-09-26       Impact factor: 16.971

Review 4.  Is telomerase a viable target in cancer?

Authors:  C M Buseman; W E Wright; J W Shay
Journal:  Mutat Res       Date:  2011-07-23       Impact factor: 2.433

5.  Allosteric inhibitors of telomerase: oligonucleotide N3'-->P5' phosphoramidates.

Authors:  Ronald Pruzan; Krisztina Pongracz; Kimberly Gietzen; Gerald Wallweber; Sergei Gryaznov
Journal:  Nucleic Acids Res       Date:  2002-01-15       Impact factor: 16.971

Review 6.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

7.  New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163.

Authors:  Rintaro Hashizume; Tomoko Ozawa; Sergei M Gryaznov; Andrew W Bollen; Kathleen R Lamborn; William H Frey; Dennis F Deen
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

8.  Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts.

Authors:  Tomoko Ozawa; Sergei M Gryaznov; Lily J Hu; Krisztina Pongracz; Raquel A Santos; Andrew W Bollen; Kathleen R Lamborn; Dennis F Deen
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

9.  Chimeric bifunctional oligonucleotides as a novel tool to invade telomerase assembly.

Authors:  Dulat Azhibek; Maria Zvereva; Timofei Zatsepin; Maria Rubtsova; Olga Dontsova
Journal:  Nucleic Acids Res       Date:  2014-07-31       Impact factor: 16.971

Review 10.  Targeting telomerase-expressing cancer cells.

Authors:  Michel M Ouellette; Woodring E Wright; Jerry W Shay
Journal:  J Cell Mol Med       Date:  2011-07       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.